{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:48:25Z","timestamp":1789645705331,"version":"4.0.0"},"reference-count":27,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>Secondary oral vancomycin prophylaxis (OVP) has been used in adults with a history of Clostridioides difficile infection (CDI) while receiving systemic antibiotics to prevent CDI recurrence. However, this practice has not been studied in pediatric patients. The objective of this study was to assess the utility of secondary OVP in pediatric patients with previous CDI who received subsequent antibiotic exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>A multicampus, retrospective cohort evaluation was conducted among patients aged \u226418 years with any history of clinical CDI and receiving systemic antibiotics in a subsequent encounter from 2013\u20132019. Patients who received concomitant OVP with antibiotics were compared with unexposed patients. The primary outcome was CDI recurrence within 8 weeks after antibiotic exposure. Infection with vancomycin-resistant enterococci and risk factors for CDI recurrence were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>A total of 148 patients were screened, of which 30 and 44 patients received OVP and no OVP, respectively. Patients who received OVP had greater antibiotic use and hospital lengths of stay. The incidence of CDI recurrence within 8 weeks of antibiotic exposure was significantly lower in patients who received OVP (3% vs 25%; P = .02) despite this group having notably more risk factors for recurrence. There were no vancomycin-resistant enterococci infections in any patients within either group. After adjustment in a multivariable analysis, secondary OVP was associated with less risk of recurrence (odds ratio, 0.10; 95% confidence interval, 0.01\u20130.86; P = .04).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Secondary OVP while receiving systemic antibiotics reduces the risk of recurrent CDI in pediatric patients with a history of CDI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2020-031807","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T08:25:20Z","timestamp":1627633520000},"source":"Crossref","is-referenced-by-count":19,"title":["Oral Vancomycin as Secondary Prophylaxis for <i>Clostridioides difficile<\/i> Infection"],"prefix":"10.1542","volume":"148","author":[{"given":"Hongkai","family":"Bao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Montefiore Medical Center, The Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lighter","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Dubrovskaya","sequence":"additional","affiliation":[{"name":"Medicine, New York University School of Medicine, New York, New York"},{"name":"Department of Pharmacy, NYU Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Merchan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NYU Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Siegfried","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NYU Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Medicine, New York University School of Medicine, New York, New York"},{"name":"Department of Pharmacy, NYU Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Pung","family":"Jen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Newark Beth Israel Medical Center, Newark, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2021,8,1]]},"reference":[{"issue":"12","key":"2021121007461140500_B1","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/ajg.2016.417","article-title":"Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections","volume":"111","author":"Carignan","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2021121007461140500_B2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2021121007461140500_B3","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1017\/ice.2019.88","article-title":"Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses","volume":"40","author":"Caroff","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"2021121007461140500_B4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/ciw401","article-title":"Efficacy of oral vancomycin in preventing recurrent clostridium difficile infection in patients treated with systemic antimicrobial agents","volume":"63","author":"Van Hise","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2021121007461140500_B5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0897190019825994","article-title":"Long-term efficacy of oral vancomycin prophylaxis for the prevention of clostridium difficile recurrence","volume":"33","author":"Knight","year":"2012","journal-title":"J Pharm Pract"},{"issue":"1","key":"2021121007461140500_B6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/MPG.0b013e3181d29767","article-title":"Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life","volume":"51","author":"Jangi","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"2021121007461140500_B7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jinf.2011.05.016","article-title":"Clostridium difficile in children: colonisation and disease","volume":"63","author":"Enoch","year":"2011","journal-title":"J Infect"},{"issue":"3","key":"2021121007461140500_B8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005176-200009000-00004","article-title":"Pediatric Clostridium difficile: a phantom menace or clinical reality?","volume":"31","author":"McFarland","year":"2000","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"2021121007461140500_B9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MPG.0000000000000553","article-title":"Novel risk factors for recurrent Clostridium difficile infection in children","volume":"60","author":"Nicholson","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"2021121007461140500_B10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/cid\/ciu302","article-title":"High colonization rate and prolonged shedding of Clostridium difficile in pediatric oncology patients","volume":"59","author":"Dominguez","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2021121007461140500_B11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3201\/eid1604.090680","article-title":"Clostridium difficile infections among hospitalized children, United States, 1997-2006","volume":"16","author":"Zilberberg","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"2021121007461140500_B12","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1542\/peds.2008-0469","article-title":"Epidemiological features of Clostridium difficile-associated disease among inpatients at children\u2019s hospitals in the United States, 2001-2006","volume":"122","author":"Kim","year":"2008","journal-title":"Pediatrics"},{"issue":"5","key":"2021121007461140500_B13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archpediatrics.2010.282","article-title":"Clostridium difficile infection in hospitalized children in the United States","volume":"165","author":"Nylund","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"2021121007461140500_B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cit155","article-title":"Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children","volume":"57","author":"Sammons","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"31","key":"2021121007461140500_B15","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.18.00407","article-title":"Guideline for the management of clostridium difficile infection in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation recipients","volume":"36","author":"Diorio","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021121007461140500_B16","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1128\/AAC.00090-08","article-title":"Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease","volume":"52","author":"Al-Nassir","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2021121007461140500_B17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/cid\/ciw424","article-title":"Editorial commentary: potential risks and rewards with prophylaxis for clostridium difficile infection","volume":"63","author":"Johnson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2021121007461140500_B18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/cid\/ciz966","article-title":"Effectiveness of oral vancomycin for prevention of healthcare facility-onset clostridioides difficile infection in targeted patients during systemic antibiotic exposure","volume":"71","author":"Johnson","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2021121007461140500_B19","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/jac\/dkt129","article-title":"Community-associated Clostridium difficile infection and antibiotics: a meta-analysis","volume":"68","author":"Deshpande","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2021121007461140500_B20","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2021121007461140500_B21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1542\/hpeds.2015-0170","article-title":"Risk factors for recurrent Clostridium difficile infection in pediatric inpatients","volume":"6","author":"Schwab","year":"2016","journal-title":"Hosp Pediatr"},{"issue":"1","key":"2021121007461140500_B22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/INF.0000000000002053","article-title":"Analysis of treatment outcomes for recurrent clostridium difficile infections and fecal microbiota transplantation in a pediatric hospital","volume":"38","author":"Aldrich","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2021121007461140500_B23","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkr508","article-title":"Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics","volume":"67","author":"Hensgens","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2021121007461140500_B24","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/phar.1644","article-title":"Probiotics and fecal microbiota transplant for primary and secondary prevention of Clostridium difficile infection","volume":"35","author":"Crow","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"7","key":"2021121007461140500_B25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1017\/ice.2018.84","article-title":"Microbial preparations (probiotics) for the prevention of clostridium difficile infection in adults and children: an individual patient data meta-analysis of 6,851 participants","volume":"39","author":"Johnston","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"2021121007461140500_B26","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/cid\/ciz1149","article-title":"Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE)","volume":"71","author":"Wolf","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2021121007461140500_B27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/cid\/cis430","article-title":"Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain","volume":"55","author":"Petrella","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-031807\/1182700\/peds_2020031807.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-031807\/1182700\/peds_2020031807.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T19:20:02Z","timestamp":1639164002000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/148\/2\/e2020031807\/179744\/Oral-Vancomycin-as-Secondary-Prophylaxis-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,1]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2020-031807","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,1]]},"article-number":"e2020031807"}}